中華民國血液病學會

1. Which statement is True?

A. Mild proteinuria and microscopic hematuria are the most common renal clinical presentations seen with WM.

B. Glomerular diseases are the most common renal manifestation seen in WM.

C. Immunoglobulin light chain (AL) amyloidosis and cryoglobulinemic glomerulonephritis are the two predominant glomerular pathologies seen in WM.

D. All of the above.

2. Which statement is False?

A. A cohort study indicated that the median overall survival for the patients with biopsy-proven WM-related kidney disease was shorter than the remaining cohort.

B. The cumulative incidence of WM-associated nephropathy at 15 years was noted to be around 0.5% in a recent retrospective study.

C. Patients with amyloid-related glomerulopathy had the highest rate of progression to ESKD.

D. Patients with any positive findings (urinalysis, proteinuria assessment, complement levels and cryoglobulin levels) would benefit from early nephrology consultation.

3. Which statement is false?

A. Hematologic response and kidney outcomes have markedly improved with the use of newer cancer and targeted therapies.

B. Zanubrutinib or ibrutinib +/- rituximab is the preferred primary therapy for WM according to NCCN guidance.

C. Plasmapheresis should be considered before treatment with Rituximab in WM patients with IgM>3000 mg/dL according to NCCN guidance.

D. BUN/creatinine, electrolytes, albumin, calcium are the essential workup items.